Free Trial

Absci Q4 2022 Earnings Report

Absci logo
$3.16 +0.17 (+5.69%)
(As of 01:15 PM ET)

Absci EPS Results

Actual EPS
-$0.21
Consensus EPS
-$0.24
Beat/Miss
Beat by +$0.03
One Year Ago EPS
N/A

Absci Revenue Results

Actual Revenue
$1.56 million
Expected Revenue
$4.06 million
Beat/Miss
Missed by -$2.50 million
YoY Revenue Growth
N/A

Absci Announcement Details

Quarter
Q4 2022
Time
N/A
Coins Set to Soar with a Pro-Crypto White House (Ad)

Coins Set to Soar with a Pro-Crypto White House President-Elect Donald Trump is reported to be holding over $3 Million worth of crypto – and he's not the only one at the top interested in digital assets…

Click here to reserve your free seat at the Crypto Community Summit

Absci Earnings Headlines

Absci Co. (NASDAQ:ABSI) Receives $8.67 Average PT from Analysts
Coins Set to Soar with a Pro-Crypto White House
Coins Set to Soar with a Pro-Crypto White House President-Elect Donald Trump is reported to be holding over $3 Million worth of crypto – and he's not the only one at the top interested in digital assets…
Absci management to meet virtually with KeyBanc
Absci (NASDAQ:ABSI) Stock, Option Chain
See More Absci Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Absci? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Absci and other key companies, straight to your email.

About Absci

Absci Corporation operates as a data-first generative artificial intelligence (AI) drug creation company in the United States. The company combines AI with scalable wet lab technologies to create biologics for patients. Its integrated drug creation platform is designed to improve upon traditional biologic drug discovery by using AI to simultaneously optimize multiple drug characteristics that may be important to development and therapeutic benefit. The company was founded in 2011 and is headquartered in Vancouver, Washington.

View Absci Profile

More Earnings Resources from MarketBeat